Terms: = Ovarian cancer AND HOXA9, HOX1, 3205, ENSG00000078399, HOX1G, P31269
29 results:
1. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
Wang Z; Yang L; Su X; Wu X; Su R
J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
[TBL] [Abstract] [Full Text] [Related]
2. High
Li XF; Zhang HB; Huo Y
J Int Med Res; 2022 Nov; 50(11):3000605221135864. PubMed ID: 36366735
[TBL] [Abstract] [Full Text] [Related]
3. Circ_CDR1as: A circular RNA with roles in the carcinogenesis.
Ghafouri-Fard S; Khoshbakht T; Hussen BM; Sarfaraz S; Taheri M; Ayatollahi SA
Pathol Res Pract; 2022 Aug; 236():153968. PubMed ID: 35667198
[TBL] [Abstract] [Full Text] [Related]
4. hoxa9-methylated DNA as a diagnostic biomarker of ovarian malignancy.
Faaborg L; Jakobsen A; Waldstrøm M; Petersen CB; Andersen RF; Steffensen KD
Biomark Med; 2021 Oct; 15(15):1309-1317. PubMed ID: 34514844
[No Abstract] [Full Text] [Related]
5. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; ; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C
Gynecol Oncol; 2021 Sep; 162(3):720-727. PubMed ID: 34454680
[TBL] [Abstract] [Full Text] [Related]
6. Analysis of hoxa9 methylated ctDNA in ovarian cancer using sense-antisense measurement.
Faaborg L; Fredslund Andersen R; Waldstrøm M; Høgdall E; Høgdall C; Adimi P; Jakobsen A; Dahl Steffensen K
Clin Chim Acta; 2021 Nov; 522():152-157. PubMed ID: 34419462
[TBL] [Abstract] [Full Text] [Related]
7. Detection of aberrant methylation of hoxa9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract] [Full Text] [Related]
8. Circulating hoxa9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Rusan M; Andersen RF; Jakobsen A; Steffensen KD
Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
[TBL] [Abstract] [Full Text] [Related]
9. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract] [Full Text] [Related]
10. Delta tocotrienol in recurrent ovarian cancer. A phase II trial.
Thomsen CB; Andersen RF; Steffensen KD; Adimi P; Jakobsen A
Pharmacol Res; 2019 Mar; 141():392-396. PubMed ID: 30639384
[TBL] [Abstract] [Full Text] [Related]
11. Annual Report of the Committee on Gynecologic Oncology, Japan Society of Obstetrics and Gynecology: Patient Annual Report for 2014 and Treatment Annual Report for 2009.
Saito T; Takahashi F; Katabuchi H;
J Obstet Gynaecol Res; 2017 Nov; 43(11):1667-1677. PubMed ID: 28892220
[TBL] [Abstract] [Full Text] [Related]
12. Overexpression of microRNA-196b Accelerates Invasiveness of cancer Cells in Recurrent Epithelial ovarian cancer Through Regulation of Homeobox A9.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL
Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653
[TBL] [Abstract] [Full Text] [Related]
13. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), hoxa9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
[TBL] [Abstract] [Full Text] [Related]
14. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer.
Xing BL; Li T; Tang ZH; Jiao L; Ge SM; Qiang X; OuYang J
Genet Mol Res; 2015 May; 14(2):4532-40. PubMed ID: 25966226
[TBL] [Abstract] [Full Text] [Related]
15. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract] [Full Text] [Related]
16. hoxa9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin.
Ko SY; Naora H
Mol Cancer; 2014 Jul; 13():170. PubMed ID: 25023983
[TBL] [Abstract] [Full Text] [Related]
17. HOX genes and their role in the development of human cancers.
Bhatlekar S; Fields JZ; Boman BM
J Mol Med (Berl); 2014 Aug; 92(8):811-23. PubMed ID: 24996520
[TBL] [Abstract] [Full Text] [Related]
18. Expression of the homeobox gene hoxa9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype.
Ko SY; Ladanyi A; Lengyel E; Naora H
Am J Pathol; 2014 Jan; 184(1):271-81. PubMed ID: 24332016
[TBL] [Abstract] [Full Text] [Related]
19. Associated analysis of DNA methylation for cancer detection using CCP-based FRET technique.
Zhang J; Xing B; Song J; Zhang F; Nie C; Jiao L; Liu L; Lv F; Wang S
Anal Chem; 2014 Jan; 86(1):346-50. PubMed ID: 24320047
[TBL] [Abstract] [Full Text] [Related]
20. hoxa9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.
Ko SY; Barengo N; Ladanyi A; Lee JS; Marini F; Lengyel E; Naora H
J Clin Invest; 2012 Oct; 122(10):3603-17. PubMed ID: 22945634
[TBL] [Abstract] [Full Text] [Related]
[Next]